Canadians Face Longer Wait Times for Drug Approvals: A Comparative Analysis
A recent study from the Fraser Institute reveals a striking disparity in drug approval processes between Canada, the United States, and Europe. The report highlights a significant challenge faced by Canadians, who endure longer wait times for new medications compared to their American and European counterparts.
Between 2020 and 2025, a total of 194 drugs were approved in both Canada and the U.S. However, the data shows a substantial difference in approval timelines. On average, drugs received approval 90 weeks earlier in the U.S. during this period.
In contrast, Canada and Europe approved 174 drugs during the same timeframe, with Europeans benefiting from an average approval lead of 65 weeks. This disparity in approval times raises questions about the underlying factors influencing the regulatory processes in these regions.
The report identifies the submission dates of new drugs to Health Canada as the primary cause of these delays. The authors suggest that the lag in approval times indicates a reluctance by pharmaceutical companies to introduce new drugs in Canada due to several factors. These include Canada's smaller market size, less robust intellectual property protections, and stringent federal pricing policies.
This analysis underscores the importance of addressing these regulatory challenges to ensure timely access to essential medications for Canadians.
